购物车
您的购物车当前为空
别名 斯妥尤单抗, Ha15-10ac12.1, Ha15-10ac12, AGS15C
Sirtratumab(AGS15C / Ha15-10ac12)是一种靶向 SLITRK6 的人源单克隆抗体。 Sirtratumab 可用于癌症研究,特别是在 SLITRK6 高表达的肿瘤模型中,用于研究 SLITRK6 对肿瘤生长、增殖、迁移或其他生物学行为的作用。作为 ADC 开发的候选抗体,基于 Sirtratumab 的抗体–药物偶联物(Sirtratumab vedotin / AGS15E)已被开发,用于将细胞毒药物选择性递送至 SLITRK6 阳性肿瘤细胞,从而提高靶向性。

为众多的药物研发团队赋能,
让新药发现更简单!
Sirtratumab(AGS15C / Ha15-10ac12)是一种靶向 SLITRK6 的人源单克隆抗体。 Sirtratumab 可用于癌症研究,特别是在 SLITRK6 高表达的肿瘤模型中,用于研究 SLITRK6 对肿瘤生长、增殖、迁移或其他生物学行为的作用。作为 ADC 开发的候选抗体,基于 Sirtratumab 的抗体–药物偶联物(Sirtratumab vedotin / AGS15E)已被开发,用于将细胞毒药物选择性递送至 SLITRK6 阳性肿瘤细胞,从而提高靶向性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,650 | 现货 | |
| 5 mg | ¥ 4,970 | 现货 | |
| 10 mg | ¥ 6,880 | 现货 | |
| 25 mg | ¥ 9,870 | 现货 | |
| 50 mg | ¥ 13,700 | 现货 |
| 产品描述 | Sirtratumab (also known as AGS15C / Ha15-10ac12) is a human monoclonal antibody targeting SLITRK6. It is used in cancer research, particularly in tumor models with high SLITRK6 expression, to investigate the role of SLITRK6 in tumor growth, proliferation, migration, and other biological processes. As a candidate antibody for ADC development, an antibody–drug conjugate derived from Sirtratumab (Sirtratumab vedotin / AGS15E) has been developed to selectively deliver cytotoxic agents to SLITRK6-positive tumor cells, thereby enhancing targeting specificity. |
| 别名 | 斯妥尤单抗, Ha15-10ac12.1, Ha15-10ac12, AGS15C |
| 反应种属 | Human |
| 应用 | ELISA FCM Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | <1.0 EU/mg |
| 同型 | Human IgG2 kappa |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 基因ID | |
| Uniprot ID | |
| 靶点 | SLITRK6 |
| 分子量 | ~150 kDa |
| CAS No. | 1824663-82-2 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
对于不同动物的给药剂量换算,您也可以参考 更多